Compare INTS & NDLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTS | NDLS |
|---|---|---|
| Founded | 2012 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8M | 68.7M |
| IPO Year | 2021 | 2013 |
| Metric | INTS | NDLS |
|---|---|---|
| Price | $4.05 | $15.14 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $38.00 | N/A |
| AVG Volume (30 Days) | ★ 39.3K | 26.2K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $495,089,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.37 |
| 52 Week Low | $0.19 | $0.47 |
| 52 Week High | $8.06 | $15.42 |
| Indicator | INTS | NDLS |
|---|---|---|
| Relative Strength Index (RSI) | 46.47 | 68.54 |
| Support Level | $0.32 | $0.59 |
| Resistance Level | $8.06 | N/A |
| Average True Range (ATR) | 0.24 | 0.84 |
| MACD | 0.08 | 0.07 |
| Stochastic Oscillator | 91.80 | 91.08 |
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services. It is focused on offering customers flavorful, cooked-to-order dishes in a warm and welcoming environment at an attractive value. It has approximately 340 company-owned restaurants and 83 franchise restaurants in 31 states.